Projects | DeMarcoLab

RESEARCH STUDIES

IMPACT-AD is a Canada-wide study to develop a comprehensive understanding of how Alzheimer’s disease biomarker testing impacts medical and personal decision making, and health care costs. The goal of IMPACT-AD is to inform positive change in the health care system to improve care and support for individuals living with Alzheimer’s disease, and their families.

Study enrollment sites are located in: Vancouver, Prince George, Calgary, Edmonton, London, Kitchener/Waterloo, Toronto, Peterborough, Ottawa, Montreal, Quebec City and St. John

Learn more at impactAD.org

IMPACT-AD British Columbia focuses on the health care system in the province of British Columbia. IMPACT-AD British Columbia is investigating how Alzheimer’s disease biomarker testing impacts medical and personal decision making, and health care costs.

Learn more at impactAD.org

COVID-19

In response to the COVID-19 pandemic, we leveraged our experience in protein-based diagnostics, including rapid novel assay development and serological testing, to contribute to the fight against COVID-19. A few of our outputs are noted below.  

Research in the news: 

Ensuring Canadian researchers are well equipped to tackle the pandemic. Canadian Foundation for Innovation 

New study casts doubt on time between COVID-19 vaccine doses. The Globe and Mail, March 26, 2021

Long-term care residents show weaker immune response to first dose of vaccine. Vancouver Sun. March 26, 2021

Research articles: 

SARS-CoV-2 (COVID-19) Serology: A Review and Assessment of Potential Implications for Clinical Practice, Laboratory Medicine, and Public Health. Canadian Medical Association Journal. 2020;192(34):E973-E979. 

Comprehensive immune profiling of a kidney transplant recipient with peri-operative SARS-CoV-2 infection: A case report. Frontiers Immunology. 2021;12:3834. 

Humoral immune responses to COVID-19 vaccination in people living with HIV on suppressive antiretroviral therapy. medRxiv. October 4, 2021. 

Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine. medRxiv. March 24, 2021.